BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumar SK, Bensinger WI, Zimmerman TM, Reeder CB, Berenson JR, Berg D, Hui AM, Gupta N, Di Bacco A, Yu J. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood. 2014;124:1047-1055. [PMID: 24904120 DOI: 10.1182/blood-2014-01-548941] [Cited by in Crossref: 148] [Cited by in F6Publishing: 129] [Article Influence: 21.1] [Reference Citation Analysis]
Number Citing Articles
1 Gonsalves WI, Godby K, Kumar SK, Costa LJ. Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma. Am J Hematol 2016;91:101-8. [PMID: 26214377 DOI: 10.1002/ajh.24129] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kumar SK, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsonis MC, Spencer A, Gupta N, Teng Z, Byrne C, Labotka R, Dimopoulos MA. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. Br J Haematol 2019;184:536-46. [PMID: 30460684 DOI: 10.1111/bjh.15679] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
3 Bergin K, Yuen F, Wallington-Beddoe C, Kalff A, Sirdesai S, Reynolds J, Spencer A. A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial. Br J Haematol 2021;194:580-6. [PMID: 33991421 DOI: 10.1111/bjh.17504] [Reference Citation Analysis]
4 Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14:417-433. [PMID: 28117417 DOI: 10.1038/nrclinonc.2016.206] [Cited by in Crossref: 343] [Cited by in F6Publishing: 275] [Article Influence: 85.8] [Reference Citation Analysis]
5 Wardill HR, Van Sebille YZ, Mander KA, Gibson RJ, Logan RM, Bowen JM, Sonis ST. Toll-like receptor 4 signaling: A common biological mechanism of regimen-related toxicities. Cancer Treatment Reviews 2015;41:122-8. [DOI: 10.1016/j.ctrv.2014.11.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
6 Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. Br J Haematol 2016;174:748-59. [PMID: 27196567 DOI: 10.1111/bjh.14125] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
7 Bladé J, Rosiñol L, Fernández de Larrea C. How I treat relapsed myeloma. Blood 2015;125:1532-40. [PMID: 25587037 DOI: 10.1182/blood-2014-10-551531] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
8 Agarwal A, Chow E, Bhutani M, Voorhees PM, Friend R, Usmani SZ. Practical Considerations in Managing Relapsed Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2017;17:69-77. [PMID: 27986429 DOI: 10.1016/j.clml.2016.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
9 Hinsley S, Walker K, Sherratt D, Bailey L, Reed S, Flanagan L, McKee S, Brudenell Straw F, Dawkins B, Meads D, Auner HW, Kaiser MF, Cook M, Brown S, Cook G; Myeloma UK Clinical Trials Network. The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor. Trials 2020;21:826. [PMID: 33008427 DOI: 10.1186/s13063-020-04739-8] [Reference Citation Analysis]
10 Gupta VA, Ackley J, Kaufman JL, Boise LH. BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. Blood Lymphat Cancer 2021;11:11-24. [PMID: 33737856 DOI: 10.2147/BLCTT.S245191] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
11 Tundo GR, Sbardella D, Santoro AM, Coletta A, Oddone F, Grasso G, Milardi D, Lacal PM, Marini S, Purrello R, Graziani G, Coletta M. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges. Pharmacol Ther 2020;213:107579. [PMID: 32442437 DOI: 10.1016/j.pharmthera.2020.107579] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
12 Castillo JJ, Hunter ZR, Yang G, Argyropoulos K, Palomba ML, Treon SP. Future therapeutic options for patients with Waldenström macroglobulinemia. Best Pract Res Clin Haematol 2016;29:206-15. [PMID: 27825467 DOI: 10.1016/j.beha.2016.08.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
13 Gupta N, Hanley MJ, Venkatakrishnan K, Bessudo A, Rasco DW, Sharma S, O'Neil BH, Wang B, Liu G, Ke A, Patel C, Rowland Yeo K, Xia C, Zhang X, Esseltine DL, Nemunaitis J. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis. J Clin Pharmacol 2018;58:180-92. [PMID: 28800141 DOI: 10.1002/jcph.988] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
14 Park JE, Miller Z, Jun Y, Lee W, Kim KB. Next-generation proteasome inhibitors for cancer therapy. Transl Res 2018;198:1-16. [PMID: 29654740 DOI: 10.1016/j.trsl.2018.03.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
15 Oka S, Ono K. Successful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome. Clin Case Rep 2021;9:e04287. [PMID: 34194792 DOI: 10.1002/ccr3.4287] [Reference Citation Analysis]
16 Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. Cancer Sci 2015;106:438-46. [PMID: 25613668 DOI: 10.1111/cas.12616] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
17 Podar K, Pecherstorfer M. Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma. Expert Opin Pharmacother 2017;18:1061-79. [PMID: 28604120 DOI: 10.1080/14656566.2017.1340942] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
18 Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE, Hu S, Medeiros LJ, Ford RJ, Pham LV. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 2018;9:346-60. [PMID: 29416618 DOI: 10.18632/oncotarget.20378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
19 Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D, Jakubowiak AJ, Reich S, Trikha M, Anderson KC. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood 2016;127:2693-700. [PMID: 27009059 DOI: 10.1182/blood-2015-12-686378] [Cited by in F6Publishing: 44] [Reference Citation Analysis]
20 Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. ESMO Open 2019;4:e000570. [PMID: 31555488 DOI: 10.1136/esmoopen-2019-000570] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
21 Larocca A, Mina R, Gay F, Bringhen S, Boccadoro M. Emerging drugs and combinations to treat multiple myeloma. Oncotarget. 2017;8:60656-60672. [PMID: 28948001 DOI: 10.18632/oncotarget.19269] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
22 Smolewski P, Rydygier D. Ixazomib: an investigational drug for the treatment of lymphoproliferative disorders. Expert Opinion on Investigational Drugs 2019;28:421-33. [DOI: 10.1080/13543784.2019.1596258] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
23 Fuchs O. Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. CHDDT 2019;19:51-78. [DOI: 10.2174/1871529x18666180522073855] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
24 Zheleznyak A, Shokeen M, Achilefu S. Nanotherapeutics for multiple myeloma. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2018;10:e1526. [PMID: 29701006 DOI: 10.1002/wnan.1526] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Zanwar S, Abeykoon JP, Kapoor P. Ixazomib: a novel drug for multiple myeloma. Expert Review of Hematology 2018;11:761-71. [DOI: 10.1080/17474086.2018.1518129] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
26 Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A. Treating Multiple Myeloma Patients With Oral Therapies. Clin Lymphoma Myeloma Leuk 2017;17:243-51. [PMID: 28347676 DOI: 10.1016/j.clml.2017.02.024] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
27 Moreau P. Oral therapy for multiple myeloma: ixazomib arriving soon. Blood 2014;124:986-7. [PMID: 25124778 DOI: 10.1182/blood-2014-06-581611] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
28 Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma. Ann Hematol 2020;99:1793-804. [PMID: 32613281 DOI: 10.1007/s00277-020-04149-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: a review about the future. J Hematol Oncol 2016;9:52. [PMID: 27363832 DOI: 10.1186/s13045-016-0282-1] [Cited by in Crossref: 96] [Cited by in F6Publishing: 86] [Article Influence: 19.2] [Reference Citation Analysis]
30 Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, Horowitz MM. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant 2015;21:202-24. [PMID: 25445636 DOI: 10.1016/j.bbmt.2014.10.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
31 Lonial S. Treatment of MM: Upcoming Novel Therapies. Cancer Treat Res 2016;169:195-205. [PMID: 27696264 DOI: 10.1007/978-3-319-40320-5_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Glavey SV, Ghobrial IM. American Society of Hematology Annual Meeting 2014: highlights in multiple myeloma. Expert Review of Hematology 2015;8:273-5. [DOI: 10.1586/17474086.2015.1029449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
33 Artschwager R, Ward DJ, Gannon S, Brouwer AJ, van de Langemheen H, Kowalski H, Liskamp RMJ. Potent and Highly Selective Inhibitors of the Proteasome Trypsin-like Site by Incorporation of Basic Side Chain Containing Amino Acid Derived Sulfonyl Fluorides. J Med Chem 2018;61:5395-411. [DOI: 10.1021/acs.jmedchem.8b00685] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
34 Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics 2018;15:1033-52. [PMID: 30427223 DOI: 10.1080/14789450.2018.1543595] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
35 Martinez-Iglesias O, Casas-Pais A, Castosa R, Díaz-Díaz A, Roca-Lema D, Concha Á, Cortés Á, Gago F, Figueroa A. Hakin-1, a New Specific Small-Molecule Inhibitor for the E3 Ubiquitin-Ligase Hakai, Inhibits Carcinoma Growth and Progression. Cancers (Basel) 2020;12:E1340. [PMID: 32456234 DOI: 10.3390/cancers12051340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Gupta N, Hanley MJ, Diderichsen PM, Yang H, Ke A, Teng Z, Labotka R, Berg D, Patel C, Liu G, van de Velde H, Venkatakrishnan K. Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. Clin Pharmacol Ther 2019;105:376-87. [PMID: 29446068 DOI: 10.1002/cpt.1047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
37 Richardson PG, Kumar S, Laubach JP, Paba-Prada C, Gupta N, Berg D, van de Velde H, Moreau P. New developments in the management of relapsed/refractory multiple myeloma - the role of ixazomib. J Blood Med 2017;8:107-21. [PMID: 28860887 DOI: 10.2147/JBM.S102328] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 3.8] [Reference Citation Analysis]
38 Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood 2017;130:597-605. [PMID: 28550039 DOI: 10.1182/blood-2017-03-771220] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 17.3] [Reference Citation Analysis]
39 Fan Y, Liang Z, Zhang J, You G. Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions. Pharmaceutics 2021;13:314. [PMID: 33670955 DOI: 10.3390/pharmaceutics13030314] [Reference Citation Analysis]
40 Ludwig H, Poenisch W, Knop S, Egle A, Schreder M, Lechner D, Hajek R, Gunsilius E, Krenosz KJ, Petzer A, Weisel K, Niederwieser D, Einsele H, Willenbacher W, Melchardt T, Greil R, Zojer N. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma. Br J Cancer 2019;121:751-7. [PMID: 31558804 DOI: 10.1038/s41416-019-0581-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 Baljevic M, Orlowski RZ. Pharmacodynamics and pharmacokinetics of proteasome inhibitors for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism & Toxicology 2019;15:459-73. [DOI: 10.1080/17425255.2019.1621839] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
42 San-Miguel JF, Echeveste Gutierrez MA, Špicka I, Mateos MV, Song K, Craig MD, Bladé J, Hájek R, Chen C, Di Bacco A, Estevam J, Gupta N, Byrne C, Lu V, van de Velde H, Lonial S. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. Haematologica 2018;103:1518-26. [PMID: 29954932 DOI: 10.3324/haematol.2017.185991] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
43 Smith DC, Kalebic T, Infante JR, Siu LL, Sullivan D, Vlahovic G, Kauh JS, Gao F, Berger AJ, Tirrell S, Gupta N, Di Bacco A, Berg D, Liu G, Lin J, Hui AM, Thompson JA. Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. Invest New Drugs 2015;33:652-63. [PMID: 25777468 DOI: 10.1007/s10637-015-0230-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
44 Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 2019;35:204-220.e9. [PMID: 30753823 DOI: 10.1016/j.ccell.2019.01.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
45 Gentile M, Offidani M, Vigna E, Corvatta L, Recchia AG, Morabito L, Morabito F, Gentili S. Ixazomib for the treatment of multiple myeloma. Expert Opin Investig Drugs 2015;24:1287-98. [PMID: 26138345 DOI: 10.1517/13543784.2015.1065250] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
46 Fogli S, Galimberti S, Gori V, Del Re M, Danesi R. Pharmacology differences among proteasome inhibitors: Implications for their use in clinical practice. Pharmacol Res 2021;167:105537. [PMID: 33684510 DOI: 10.1016/j.phrs.2021.105537] [Reference Citation Analysis]
47 Fotiou D, Gavriatopoulou M, Terpos E. Multiple Myeloma and Thrombosis: Prophylaxis and Risk Prediction Tools. Cancers (Basel) 2020;12:E191. [PMID: 31940972 DOI: 10.3390/cancers12010191] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 11.0] [Reference Citation Analysis]
48 Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Rajkumar SV, Richardson PG. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance. Leukemia 2019;33:1736-46. [PMID: 30696949 DOI: 10.1038/s41375-019-0384-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
49 Broijl A, Sonneveld P. An update in treatment options for multiple myeloma in nontransplant eligible patients. Expert Opin Pharmacother 2015;16:1945-57. [PMID: 26245702 DOI: 10.1517/14656566.2015.1075507] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
50 Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J 2019;9:56. [PMID: 31358733 DOI: 10.1038/s41408-019-0219-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
51 Dimopoulos MA, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, Matsouka C, Mparmparousi D, Gika D, Kafantari E, Ziogas D, Fotiou D, Panagiotidis I, Terpos E, Kastritis E. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. Am J Hematol 2016;91:499-502. [PMID: 26890495 DOI: 10.1002/ajh.24335] [Cited by in Crossref: 46] [Cited by in F6Publishing: 25] [Article Influence: 9.2] [Reference Citation Analysis]
52 Dingli D, Ailawadhi S, Bergsagel PL, Buadi FK, Dispenzieri A, Fonseca R, Gertz MA, Gonsalves WI, Hayman SR, Kapoor P, Kourelis T, Kumar SK, Kyle RA, Lacy MQ, Leung N, Lin Y, Lust JA, Mikhael JR, Reeder CB, Roy V, Russell SJ, Sher T, Stewart AK, Warsame R, Zeldenrust SR, Rajkumar SV, Chanan Khan AA. Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy. Mayo Clin Proc 2017;92:578-98. [PMID: 28291589 DOI: 10.1016/j.mayocp.2017.01.003] [Cited by in Crossref: 74] [Cited by in F6Publishing: 57] [Article Influence: 18.5] [Reference Citation Analysis]
53 Shah SP, Lonial S, Boise LH. When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. Mol Cancer Res 2015;13:1163-73. [PMID: 26013169 DOI: 10.1158/1541-7786.MCR-15-0135] [Cited by in Crossref: 36] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
54 Larsen JT, Kumar S. Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies. Rare Cancers Ther 2015;3:47-68. [PMID: 27182478 DOI: 10.1007/s40487-015-0009-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
55 Bonnet A, Moreau P. Safety of ixazomib for the treatment of multiple myeloma. Expert Opin Drug Saf 2017;16:973-80. [PMID: 28661711 DOI: 10.1080/14740338.2017.1344212] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
56 Gupta N, Zhang S, Pusalkar S, Plesescu M, Chowdhury S, Hanley MJ, Wang B, Xia C, Zhang X, Venkatakrishnan K, Shepard DR. A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. Invest New Drugs 2018;36:407-15. [PMID: 28932928 DOI: 10.1007/s10637-017-0509-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
57 Vogl DT, Martin TG, Vij R, Hari P, Mikhael JR, Siegel D, Wu KL, Delforge M, Gasparetto C. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leukemia & Lymphoma 2016;58:1872-9. [DOI: 10.1080/10428194.2016.1263842] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
58 Yui JC, Dispenzieri A, Leung N. Ixazomib-induced thrombotic microangiopathy. Am J Hematol. 2017;92:E53-E55. [PMID: 28133842 DOI: 10.1002/ajh.24662] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
59 Liu Y, Huang W, Lin M, Li J, Zhang J. Proteasome Inhibitors as Sensitizing Agents for Cancer Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Elsevier; 2019. pp. 207-28. [DOI: 10.1016/b978-0-12-816435-8.00013-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Mofers A, Pellegrini P, Linder S, D'Arcy P. Proteasome-associated deubiquitinases and cancer. Cancer Metastasis Rev 2017;36:635-53. [PMID: 29134486 DOI: 10.1007/s10555-017-9697-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 14.3] [Reference Citation Analysis]
61 Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S. The Diagnosis and Treatment of Multiple Myeloma. Dtsch Arztebl Int 2016;113:470-6. [PMID: 27476706 DOI: 10.3238/arztebl.2016.0470] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
62 Richardson PG, Zweegman S, O’donnell EK, Laubach JP, Raje N, Voorhees P, Ferrari RH, Skacel T, Kumar SK, Lonial S. Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy 2018;19:1949-68. [DOI: 10.1080/14656566.2018.1528229] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
63 Barac YD, Emrich F, Krutzwakd-josefson E, Schrepfer S, Sampaio LC, Willerson JT, Robbins RC, Ciechanover A, Mohr F, Aravot D, Taylor DA. The ubiquitin-proteasome system: A potential therapeutic target for heart failure. The Journal of Heart and Lung Transplantation 2017;36:708-14. [DOI: 10.1016/j.healun.2017.02.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
64 Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, Agajanian R, Boccia R, Coleman M, Moss RA, Rifkin RM, Patel P, Dixon S, Ou Y, Anderl J, Aggarwal S, Berdeja JG. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood 2016;127:3360-8. [PMID: 27207788 DOI: 10.1182/blood-2015-11-683854] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 13.4] [Reference Citation Analysis]
65 Offidani M, Corvatta L, Gentili S, Maracci L, Leoni P. Oral ixazomib maintenance therapy in multiple myeloma. Expert Rev Anticancer Ther 2016;16:21-32. [PMID: 26588946 DOI: 10.1586/14737140.2016.1123627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
66 Krishnan A, Kapoor P, Palmer JM, Tsai NC, Kumar S, Lonial S, Htut M, Karanes C, Nathwani N, Rosenzweig M, Sahebi F, Somlo G, Duarte L, Sanchez JF, Auclair D, Forman SJ, Berdeja JG. Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma. Leukemia 2018;32:1567-74. [PMID: 32082000 DOI: 10.1038/s41375-018-0038-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
67 Gupta N, Yang H, Hanley MJ, Zhang S, Liu R, Kumar S, Richardson PG, Skacel T, Venkatakrishnan K. Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Target Oncol 2017;12:643-54. [PMID: 28803351 DOI: 10.1007/s11523-017-0524-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
68 Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. Br J Haematol 2018;182:231-44. [PMID: 29938772 DOI: 10.1111/bjh.15394] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
69 Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K. Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. Clin Pharmacokinet 2019;58:431-49. [PMID: 30117017 DOI: 10.1007/s40262-018-0702-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
70 Ettari R, Zappalà M, Grasso S, Musolino C, Innao V, Allegra A. Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. Pharmacol Ther 2018;182:176-92. [PMID: 28911826 DOI: 10.1016/j.pharmthera.2017.09.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
71 Kumar SK, LaPlant B, Roy V, Reeder CB, Lacy MQ, Gertz MA, Laumann K, Thompson MA, Witzig TE, Buadi FK, Rivera CE, Mikhael JR, Bergsagel PL, Kapoor P, Hwa L, Fonseca R, Stewart AK, Chanan-Khan A, Rajkumar SV, Dispenzieri A. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J 2015;5:e338. [PMID: 26275080 DOI: 10.1038/bcj.2015.60] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
72 Orlowski RZ, Lonial S. Integration of Novel Agents into the Care of Patients with Multiple Myeloma. Clin Cancer Res 2016;22:5443-52. [PMID: 28151712 DOI: 10.1158/1078-0432.CCR-16-0861] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
73 Sidana S, Narkhede M, Elson P, Hastings D, Faiman B, Valent J, Samaras C, Hamilton K, Liu HK, Smith MR, Reu FJ. Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis. PLoS One 2017;12:e0172996. [PMID: 28278302 DOI: 10.1371/journal.pone.0172996] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
74 Garderet L, Cook G, Auner HW, Bruno B, Lokhorst H, Perez-simon JA, Sahebi F, Scheid C, Morris C, van Biezen A, Sobh M, Michallet M, Gahrton G, Schönland S, Kröger N. Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting. Leukemia & Lymphoma 2016;58:797-808. [DOI: 10.1080/10428194.2016.1228926] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
75 Shirley M. Ixazomib: First Global Approval. Drugs 2016;76:405-11. [DOI: 10.1007/s40265-016-0548-5] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 13.0] [Reference Citation Analysis]
76 Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw 2016;14:389-400. [PMID: 27059188 DOI: 10.6004/jnccn.2016.0046] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
77 Takakuwa T, Yamamura R, Ohta K, Kaneko H, Imada K, Nakaya A, Fuchida SI, Shibayama H, Matsuda M, Shimazu Y, Adachi Y, Kosugi S, Uchiyama H, Tanaka H, Hanamoto H, Shimura Y, Kanda J, Onda Y, Uoshima N, Yagi H, Yoshihara S, Hino M, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Kanakura Y, Nomura S. Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. Eur J Haematol 2021;106:555-62. [PMID: 33476404 DOI: 10.1111/ejh.13586] [Reference Citation Analysis]
78 Gupta N, Hanley MJ, Venkatakrishnan K, Perez R, Norris RE, Nemunaitis J, Yang H, Qian MG, Falchook G, Labotka R, Fu S. Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. Br J Clin Pharmacol 2016;82:728-38. [PMID: 27121262 DOI: 10.1111/bcp.12991] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
79 Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resistance Updates 2015;18:18-35. [DOI: 10.1016/j.drup.2014.12.001] [Cited by in Crossref: 110] [Cited by in F6Publishing: 101] [Article Influence: 18.3] [Reference Citation Analysis]
80 Gupta N, Hanley MJ, Venkatakrishnan K, Wang B, Sharma S, Bessudo A, Hui AM, Nemunaitis J. The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. J Clin Pharmacol 2016;56:1288-95. [PMID: 26872892 DOI: 10.1002/jcph.719] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
81 Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment options for relapsed and refractory multiple myeloma. Blood 2015;125:3085-99. [DOI: 10.1182/blood-2014-11-568923] [Cited by in Crossref: 93] [Cited by in F6Publishing: 81] [Article Influence: 15.5] [Reference Citation Analysis]
82 Al-Salama ZT, Garnock-Jones KP, Scott LJ. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma. Target Oncol 2017;12:535-42. [PMID: 28660423 DOI: 10.1007/s11523-017-0504-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
83 Suarez-Kelly LP, Kemper GM, Duggan MC, Stiff A, Noel TC, Markowitz J, Luedke EA, Yildiz VO, Yu L, Jaime-Ramirez AC, Karpa V, Zhang X, Carson WE 3rd. The combination of MLN2238 (ixazomib) with interferon-alpha results in enhanced cell death in melanoma. Oncotarget 2016;7:81172-86. [PMID: 27783987 DOI: 10.18632/oncotarget.12791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
84 Kersten MJ, Amaador K, Minnema MC, Vos JMI, Nasserinejad K, Kap M, Kastritis E, Gavriatopoulou M, Kraan W, Chamuleau MED, Deeren D, Tick LW, Doorduijn JK, Offner F, Böhmer LH, Liu RD, Pals ST, Dimopoulos MA. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. J Clin Oncol 2021;:JCO2100105. [PMID: 34388022 DOI: 10.1200/JCO.21.00105] [Reference Citation Analysis]
85 Specht L. Does Radiation Have a Role in Advanced Stage Hodgkin’s or Non-Hodgkin Lymphoma? Curr Treat Options in Oncol 2016;17. [DOI: 10.1007/s11864-015-0377-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
86 Neri P, Bahlis NJ, Paba-prada C, Richardson P. Treatment of Relapsed/Refractory Multiple Myeloma. In: Roccaro AM, Ghobrial IM, editors. Plasma Cell Dyscrasias. Cham: Springer International Publishing; 2016. pp. 169-94. [DOI: 10.1007/978-3-319-40320-5_10] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
87 Gupta N, Goh YT, Min CK, Lee JH, Kim K, Wong RS, Chim CS, Hanley MJ, Yang H, Venkatakrishnan K, Hui AM, Esseltine DL, Chng WJ. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol 2015;8:103. [PMID: 26337806 DOI: 10.1186/s13045-015-0198-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
88 Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood 2015;126:300-10. [PMID: 26031917 DOI: 10.1182/blood-2015-03-575365] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 10.3] [Reference Citation Analysis]
89 Boudreault JS, Touzeau C, Moreau P. Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials. Expert Rev Hematol 2017;10:207-15. [PMID: 28110581 DOI: 10.1080/17474086.2017.1285694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
90 Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P. An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. Onco Targets Ther 2014;7:1793-800. [PMID: 25302026 DOI: 10.2147/OTT.S49187] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
91 Gupta N, Huh Y, Hutmacher MM, Ottinger S, Hui AM, Venkatakrishnan K. Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. Cancer Chemother Pharmacol 2015;76:507-16. [PMID: 26141494 DOI: 10.1007/s00280-015-2815-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
92 Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 2018;8:70. [PMID: 30061664 DOI: 10.1038/s41408-018-0106-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
93 Xi J, Zhuang R, Kong L, He R, Zhu H, Zhang J. Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases. Eur J Med Chem 2019;182:111646. [PMID: 31521028 DOI: 10.1016/j.ejmech.2019.111646] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
94 Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood 2017;130:963-73. [PMID: 28679737 DOI: 10.1182/blood-2017-03-726703] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
95 Gupta N, Labotka R, Liu G, Hui AM, Venkatakrishnan K. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study. Invest New Drugs 2016;34:338-46. [PMID: 27039387 DOI: 10.1007/s10637-016-0346-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
96 Driscoll JJ, Brailey M. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. Cancer Metastasis Rev 2017;36:585-98. [PMID: 29052093 DOI: 10.1007/s10555-017-9698-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
97 Mishra R, Upadhyay A, Prajapati VK, Mishra A. Proteasome-mediated proteostasis: Novel medicinal and pharmacological strategies for diseases. Med Res Rev 2018;38:1916-73. [DOI: 10.1002/med.21502] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
98 Park J, Park E, Jung CK, Kang SW, Kim BG, Jung Y, Kim TH, Lim JY, Lee SE, Min CK, Won KA. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models. BMC Cancer 2016;16:247. [PMID: 27012957 DOI: 10.1186/s12885-016-2285-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
99 Xie J, Wan N, Liang Z, Zhang T, Jiang J. Ixazomib – the first oral proteasome inhibitor. Leukemia & Lymphoma 2019;60:610-8. [DOI: 10.1080/10428194.2018.1523398] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
100 Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 2014;124:1038-46. [PMID: 24920586 DOI: 10.1182/blood-2014-01-548826] [Cited by in Crossref: 153] [Cited by in F6Publishing: 134] [Article Influence: 21.9] [Reference Citation Analysis]
101 Le Ray E, Jagannath S, Palumbo A. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma. Expert Rev Hematol 2016;9:91-105. [PMID: 26558304 DOI: 10.1586/17474086.2016.1119041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
102 Obrist F, Manic G, Kroemer G, Vitale I, Galluzzi L. Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol 2015;2:e974463. [PMID: 27308423 DOI: 10.4161/23723556.2014.974463] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
103 Micheletto MLJ, Hermes TA, Bertassoli BM, Petri G, Perez MM, Fonseca FLA, Carvalho AAS, Feder D. Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice. Int J Exp Pathol 2021;102:11-21. [PMID: 33296126 DOI: 10.1111/iep.12383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 van Nieuwenhuijzen N, Frunt R, May AM, Minnema MC. Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis. Blood Cancer J 2021;11:44. [PMID: 33649328 DOI: 10.1038/s41408-021-00441-3] [Reference Citation Analysis]
105 Hou J, Jin J, Xu Y, Wu D, Ke X, Zhou D, Lu J, Du X, Chen X, Li J, Liu J, Gupta N, Hanley MJ, Li H, Hua Z, Wang B, Zhang X, Wang H, van de Velde H, Richardson PG, Moreau P. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. J Hematol Oncol 2017;10:137. [PMID: 28683766 DOI: 10.1186/s13045-017-0501-4] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
106 Pantani L, Brioli A, Tacchetti P, Zannetti BA, Mancuso K, Rocchi S, Martello M, Rizzello I, Terragna C, Zamagni E, Cavo M. Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma. Expert Rev Hematol 2016;9:315-23. [PMID: 26634945 DOI: 10.1586/17474086.2016.1127754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
107 Chhabra S. Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics. Pharmaceuticals (Basel) 2017;10:E40. [PMID: 28398261 DOI: 10.3390/ph10020040] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
108 Bianchi G, Anderson KC. Contribution of Inhibition of Protein Catabolism in Myeloma. Cancer J 2019;25:11-8. [DOI: 10.1097/ppo.0000000000000349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
109 Lefebvre J, Glezerman IG. Kidney Toxicities Associated With Novel Cancer Therapies. Adv Chronic Kidney Dis 2017;24:233-40. [PMID: 28778363 DOI: 10.1053/j.ackd.2017.05.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
110 Suzuki K, Handa H, Chou T, Ishizawa K, Takubo T, Kase Y. Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. Int J Hematol 2017;105:445-52. [PMID: 28000099 DOI: 10.1007/s12185-016-2149-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
111 Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev 2017;36:561-84. [PMID: 29196868 DOI: 10.1007/s10555-017-9707-8] [Cited by in Crossref: 131] [Cited by in F6Publishing: 104] [Article Influence: 43.7] [Reference Citation Analysis]
112 Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood 2015;125:3069-75. [PMID: 25838344 DOI: 10.1182/blood-2014-09-568899] [Cited by in Crossref: 135] [Cited by in F6Publishing: 104] [Article Influence: 22.5] [Reference Citation Analysis]
113 Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hájek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol 2017;178:571-82. [PMID: 28485007 DOI: 10.1111/bjh.14733] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
114 Salvini M, Troia R, Giudice D, Pautasso C, Boccadoro M, Larocca A. Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. Expert Opinion on Drug Metabolism & Toxicology 2017;14:91-9. [DOI: 10.1080/17425255.2018.1417388] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
115 Kumar SK, LaPlant BR, Reeder CB, Roy V, Halvorson AE, Buadi F, Gertz MA, Bergsagel PL, Dispenzieri A, Thompson MA, Crawley J, Kapoor P, Mikhael J, Stewart K, Hayman SR, Hwa YL, Gonsalves W, Witzig TE, Ailawadhi S, Dingli D, Go RS, Lin Y, Rivera CE, Rajkumar SV, Lacy MQ. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood 2016;128:2415-22. [PMID: 27702799 DOI: 10.1182/blood-2016-05-717769] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
116 Lei M, Feng H, Bai E, Zhou H, Wang J, Shi J, Wang X, Hu S, Liu Z, Zhu Y. Design, synthesis, in vitro and in vivo evaluation, and structure-activity relationship (SAR) discussion of novel dipeptidyl boronic acid proteasome inhibitors as orally available anti-cancer agents for the treatment of multiple myeloma and mechanism studies. Bioorg Med Chem 2018;26:3975-81. [PMID: 29934218 DOI: 10.1016/j.bmc.2018.06.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
117 Touzeau C, Moreau P. Ixazomib in the management of relapsed multiple myeloma. Future Oncology 2018;14:2013-20. [DOI: 10.2217/fon-2017-0710] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
118 Sonneveld P, De Wit E, Moreau P. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Critical Reviews in Oncology/Hematology 2017;112:153-70. [DOI: 10.1016/j.critrevonc.2017.02.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
119 Assouline SE, Chang J, Cheson BD, Rifkin R, Hamburg S, Reyes R, Hui AM, Yu J, Gupta N, Di Bacco A, Shou Y, Martin P. Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. Blood Cancer J 2014;4:e251. [PMID: 25325301 DOI: 10.1038/bcj.2014.71] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
120 Lipchick BC, Fink EE, Nikiforov MA. Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res 2016;105:210-5. [PMID: 26827824 DOI: 10.1016/j.phrs.2016.01.029] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
121 Scalzulli E, Grammatico S, Vozella F, Petrucci MT. Proteasome inhibitors for the treatment of multiple myeloma. Expert Opin Pharmacother 2018;19:375-86. [PMID: 29478351 DOI: 10.1080/14656566.2018.1441287] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
122 Gupta N, Diderichsen PM, Hanley MJ, Berg D, van de Velde H, Harvey RD, Venkatakrishnan K. Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. Clin Pharmacokinet 2017;56:1355-68. [PMID: 28290121 DOI: 10.1007/s40262-017-0526-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
123 Shah SP, Nooka AK, Jaye DL, Bahlis NJ, Lonial S, Boise LH. Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation. Oncotarget 2016;7:59727-41. [PMID: 27487129 DOI: 10.18632/oncotarget.10847] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
124 Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, Stewart AK, Hari P, Roy V, Vescio R, Kaufman JL, Berg D, Liao E, Di Bacco A, Estevam J, Gupta N, Hui AM, Rajkumar V, Richardson PG. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014;15:1503-12. [PMID: 25456369 DOI: 10.1016/S1470-2045(14)71125-8] [Cited by in Crossref: 181] [Cited by in F6Publishing: 87] [Article Influence: 25.9] [Reference Citation Analysis]
125 Mairinger FD, Walter RF, Theegarten D, Hager T, Vollbrecht C, Christoph DC, Worm K, Ting S, Werner R, Stamatis G, Mairinger T, Baba H, Zarogoulidis K, Huang H, Li Q, Tsakiridis K, Zarogoulidis P, Schmid KW, Wohlschlaeger J. Gene Expression Analysis of the 26S Proteasome Subunit PSMB4 Reveals Significant Upregulation, Different Expression and Association with Proliferation in Human Pulmonary Neuroendocrine Tumours. J Cancer 2014;5:646-54. [PMID: 25157275 DOI: 10.7150/jca.9955] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
126 Reese SR, Wilson NA, Huang G, Redfield RR, Zhong W, Djamali A. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model. Transplantation 2015;99:1785-95. [DOI: 10.1097/tp.0000000000000736] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
127 Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol 2015;96:1-9. [PMID: 25935605 DOI: 10.1016/j.bcp.2015.04.008] [Cited by in Crossref: 95] [Cited by in F6Publishing: 83] [Article Influence: 15.8] [Reference Citation Analysis]
128 Richardson PG, Moreau P, Laubach JP, Gupta N, Hui A, Anderson KC, San Miguel JF, Kumar S. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncology 2015;11:1153-68. [DOI: 10.2217/fon.15.9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]